Suspension and Resumption of Trading - Tianyang New Materials' controlling shareholder is planning a change in control, leading to stock suspension [1] - Taihe Water's controlling shareholder and actual controller are planning a significant matter involving the transfer of part or all of the company's shares, resulting in stock suspension [1] - Hunan Development intends to purchase 90% equity of Tongwan Hydropower held by Xiangtou Energy, with stock resuming trading tomorrow [1] Private Placement - Huali Chuantong plans to raise no more than 450 million yuan through a private placement for projects related to radiation-resistant modules, multi-mode satellite communication SOC chips, and global multi-mode navigation systems [2] Share Transfer and Buyback - XGIMI Technology's shareholder intends to transfer 1.75 million shares, accounting for 2% of the total shares [3] - Zhongheng Group plans to repurchase shares worth between 300 million to 500 million yuan [4] External Investment and Daily Operations - Fengcai Technology intends to invest 28 million yuan to acquire 9.06% of Huake Zhixin [5] - Hongjing Technology signed a 312 million yuan contract for computing power services with China Mobile Ningxia [6] - Yaxiang Integration's Singapore branch plans to bid for a project worth approximately 3.163 billion yuan [7] - Shenglong Co., Ltd. received a notification for the development of flying cars, with an expected total sales amount of 120 million yuan over five years [8] - Huadong Medicine's wholly-owned subsidiary received acceptance notice for the marketing authorization application of Semaglutide injection [9] - Guyue Longshan has raised prices on some products [10] - Chengdi Xiangjiang's wholly-owned subsidiary received a formal contract for a data center project from China Telecom Shanghai, valued at 616 million yuan [10] - Deyue Co., Ltd. plans to invest no more than 2.127 billion yuan to build a production line with an annual capacity of 16 GWh [10] - Ankai Micro released a low-power intelligent vision chip [11] Performance Changes - Xianggang Technology expects a net profit increase of 713% to 917% year-on-year in Q1 2025, driven by significant revenue growth, improved operational efficiency, and cost control [12] - SAIC Group reported March sales of 125,700 new energy vehicles, a year-on-year increase of 48.22% [13]

2025年4月1日晚，华东医药股份有限公司（股票代码：000963.SZ，以下简称"华东医药"）发布公告 称，公司全资子公司杭州中美华东制药江东有限公司（以下简称"江东公司"）收到国家药品监督管理局 （NMPA）签发的《受理通知书》，司美格鲁肽注射液上市许可申请获得受理，本次申报适应症为成人 2型糖尿病患者的血糖控制。 众所周知，全球糖尿病市场处在不断增长中，潜力巨大。柳叶刀显示，全球糖尿病患病率在过去三十余 年间显著上升。1990年至2022年，全球≥18岁成年糖尿病患者数量从1990年的约2亿激增至8.28亿。2022 年我国成年糖尿病患者人数约为1.48亿，占全球成人糖尿病总数的18%，位列全球第二，其中未治疗人 数为7800 万人，未治疗率达到 52.7%。根据国际糖尿病联盟（IDF）全球糖尿病地图，我国存在糖尿病 知晓率、治疗率、控制率三低的情况，未来糖尿病临床诊断率和治疗率将不断提升，糖尿病治疗市场将 随之持续增长。 华东医药全面布局，围绕GLP-1构筑差异化创新管线 在糖尿病用药领域，华东医药深耕近二十年，在主流治疗靶点形成了创新药和差异化仿制药产品管线全 面布局，目前商业化及在研产品达到二十余 ...

华东医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 证券代码：000963 证券简称：华东医药 公告编号：2025-019 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 3 月 31 日，华东医药股份有限公司（以下简称"公司"） 全资子公司杭州中美华东制药江东有限公司（以下简称"江东公司"） 收到国家药品监督管理局（NMPA）签发的《受理通知书》（受理号： CXSS2500040；CXSS2500041；CXSS2500042；CXSS2500043），由 江东公司申报的司美格鲁肽注射液（研发代码：HDG1901）上市许可 申请获得受理。现将有关详情公告如下： 一、该药物基本信息内容 药物名称：司美格鲁肽注射液 申请事项：境内生产药品注册上市许可 注册分类：治疗用生物制品 3.3 类 规格：1.34mg/ml，1.5ml（笔芯）；1.34mg/ml，1.5ml（预填充 注射笔）；1.34mg/ml，3ml（笔芯）；1.34mg/ml，3ml（预填充注射 笔） 申报适应症：本品适用于成人 2 型糖尿病患者的血糖控制。 申请人：杭州中 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000963 证券简称：华东医药 公告编号：2025-018 华东医药股份有限公司关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次回购注销的限制性股票为华东医药股份有限公司2022年限制性股票激励计划已授予但尚未解除 限售的部分限制性股票；本次回购注销涉及18名激励对象，回购注销的限制性股票共计18.55万股，占 本次回购注销前公司总股本比例为0.01%； 2、本次限制性股票回购价格为23.78元/股，回购款项合计4,621,985.34元，含代扣代缴个人所得税以及 相应利息； 3、本次回购注销完成后，公司总股本由1,754,262,548.00股减少至1,754,077,048.00股； 4、截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公司完成了上述限制性股票的 回购注销手续。 华东医药股份有限公司（以下简称"公司"）于2024年11月25日召开第十届董事会第三十次会议和第十届 监事会第二十次会议，并于2024年12月20日召 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-018 华东医药股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次回购注销的限制性股票为华东医药股份有限公司2022年 限制性股票激励计划已授予但尚未解除限售的部分限制性股票；本次 回购注销涉及18名激励对象，回购注销的限制性股票共计18.55万股， 占本次回购注销前公司总股本比例为0.01%； 2、本次限制性股票回购价格为23.78元/股，回购款项合计 4,621,985.34元，含代扣代缴个人所得税以及相应利息； 3、本次回购注销完成后，公司总股本由1,754,262,548.00股减少 至1,754,077,048.00股； 4、截至本公告披露日，公司已在中国证券登记结算有限责任公 司深圳分公司完成了上述限制性股票的回购注销手续。 华东医药股份有限公司（以下简称"公司"）于2024年11月25日召 开第十届董事会第三十次会议和第十届监事会第二十次会议，并于 2024年12月20日召开2024年第二次临时股东大会，审议通过了 ...

Group 1: Company Performance - China Life reported a net profit of 106.935 billion yuan for 2024, representing a year-on-year increase of 108.9% [3] - China Life's operating revenue for 2024 reached 528.567 billion yuan, up 30.5% compared to the previous year [3] - Aluminum Corporation of China announced a net profit of 12.4 billion yuan for 2024, reflecting an 85.38% year-on-year growth [4] - Broadcom Electric's net profit surged by 411.28% in 2024, with a proposed dividend of 0.70 yuan per 10 shares [10] - China Pacific Insurance's net profit for 2024 increased by 64.9%, with a proposed dividend of 10.8 yuan per 10 shares [10] Group 2: Corporate Actions - Naxin Micro announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance competitiveness and diversify financing channels [7] - Xunji Technology is planning to acquire 100% equity of Shenzhen Jiazhihong Electronics, leading to a significant asset restructuring [5] - Nasda announced the sale of its 100% stake in Lexmark International for an estimated price between 75 million and 150 million USD, significantly lower than the historical investment of 1.385 billion USD [8] - General Shares announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [9] Group 3: Market Impact - The inclusion of Southwest Design, a subsidiary of Electric Science and Technology, on the U.S. Department of Commerce's Entity List may affect its operations, although the company claims no substantial impact on business [6] - The stock of General Shares will be suspended due to potential changes in control, which may affect investor sentiment [9]

Group 1 - China Aluminum reported a net profit of 12.4 billion yuan for 2024, an increase of 85.38% year-on-year, with a proposed cash dividend of 0.135 yuan per share [1] - Lihua Technology's net profit for 2024 decreased by 25.41% to 245 million yuan, with a proposed cash dividend of 0.7 yuan per 10 shares [1][2] - Zhongjing Food achieved a net profit of 175 million yuan in 2024, up 1.81% year-on-year, proposing a cash dividend of 8 yuan per 10 shares [3][4] - Sanwei Chemical's net profit fell by 6.92% to 263 million yuan, with a proposed cash dividend of 3 yuan per 10 shares [5] - Meino Biological's project for corn protein processing has received construction approval, with an investment of approximately 391 million yuan [6][7] Group 2 - Guangdian Electric's net profit surged by 411.28% to 74.73 million yuan, proposing a cash dividend of 0.7 yuan per 10 shares [13][14] - Xin'ao Co. reported a net profit of 4.493 billion yuan for 2024, down 36.64%, with a proposed cash dividend of 10.3 yuan per 10 shares [15] - Huaren Pharmaceutical's subsidiary received approval for a raw material drug, enhancing its product line [16] - Huanxin Technology received a project confirmation from BAIC Group for two display screen products, expected to enter mass supply [17] - Haitong Development plans to purchase four bulk carriers for a total of 59.25 million USD to expand its fleet [18] Group 3 - Guochuang High-tech won a bid for an asphalt procurement project worth 128 million yuan [22][23] - Huayi Pharmaceutical's subsidiary received overseas marketing approvals for several products [24] - Haisco's innovative drug HSK41959 has received clinical trial approval [25] - Hetai Machinery's subsidiary obtained a patent for a dust-proof chain technology [28] - Le Xin Medical's fetal heart rate monitor registration renewal application has been accepted [29] Group 4 - Feilong Co. became a designated supplier for an international client's electronic oil pump project, with expected sales of approximately 160 million yuan [29] - Yunnan Copper reported a net profit of 1.265 billion yuan for 2024, down 19.9%, with a proposed cash dividend of 2.4 yuan per 10 shares [42] - China Merchants Bank's net profit increased by 1.22% to 148.39 billion yuan, proposing a cash dividend of 20 yuan per 10 shares [43] - Shuanghui Development's net profit decreased by 1.26% to 4.989 billion yuan, with a proposed cash dividend of 7.5 yuan per 10 shares [44]

HDM3019（IMB-101）是靶向 OX40L 和 TNFα 的双特异性抗体， 参与调节炎症细胞因子，抑制 T 细胞和浆细胞分化，以及自身抗体产 证券代码：000963 证券简称：华东医药 公告编号：2025-017 华东医药股份有限公司 关于全资子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 3 月 25 日，华东医药股份有限公司（以下简称"公司"） 全资子公司杭州中美华东制药有限公司（以下简称"中美华东"）收到 国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知 书》（通知书编号：2025LP00883），由中美华东申报的 HDM3019 临 床试验申请获得批准，现将有关详情公告如下： 一、该药物基本信息 | 产品名称 | HDM3019 | | --- | --- | | 申请事项 | 临床试验 | | 注册分类 | 治疗用生物制品1类 | | 受理号 | CXSL2500046 | | 适应症 | 类风湿关节炎 | | 申请人 | 杭州中美华东制药有限公司 | | 结论 | 根据《中 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-016 华东医药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"本公司"或"公司"）近日 接到控股股东中国远大集团有限责任公司（以下简称"远大集团"） 通知，获悉远大集团将其所持有的本公司部分股份办理了质押，部分 股份办理了解除质押。具体事项如下： 一、股东股份质押基本情况 | | 是否为控 | | | | 是否为 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 股股东或 | 本次质押 | 占其所 | 占公司 | 限售股 （如 | 是否 为补 | 质押起始 | | | 质押 | | | 第一大股 | 数量 | 持股份 | 总股本 | | | | 质押到期日 | 质权人 | | | 称 | | | | | 是，注 | 充质 | 日 | | | 用途 | | | 东及其一 | （股） | ...

证券代码：000963 证券简称：华东医药 公告编号：2025-015 华东医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年3月10日，华东医药股份有限公司（以下简称"公司"）全资 子公司杭州中美华东制药有限公司（以下简称"中美华东"）收到国家 药品监督管理局（NMPA）签发的《受理通知书》，中美华东申报的索 米妥昔单抗注射液（爱拉赫®/ELAHERE®）由附条件批准转为常规批 准的补充申请获得受理。现将相关情况公告如下： 一、该药物基本信息内容 药品通用名称：索米妥昔单抗注射液 英文名：Mirvetuximab Soravtansine Injection 商品名称：爱拉赫/ELAHERE 规格：100 mg（20mL）/瓶 申请事项：境外生产药品补充申请 注册分类：治疗用生物制品3.1类 受理号：JYSB2500057 申报适应症：本品适用于既往接受过1-3线系统性治疗的叶酸受体 α（FRα）阳性的铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌 成年患者。 上市许可持有人：AbbVie ...